The State Drug Administration has approved the listing of Fu Xinqibai monoclonal antibody injection.

Recently, the National Medical Products Administration approved Chongqing Jinxi Pharmaceutical Co., Ltd. to market Fuxinqibai monoclonal antibody injection, which is used for adults with acute attacks of gouty arthritis who are contraindicated, intolerant or ineffective to non-steroidal anti-inflammatory drugs and/or colchicine, and are not suitable for repeated use of corticosteroids. The marketing of this product provides new treatment options for relevant patients.